Bile duct cancer, Bowel (colorectal) cancer, Cervical cancer, Colon cancer, Head and neck cancers, Lung cancer, Melanoma, Non small cell lung cancer (NSCLC), Oesophageal cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Secondary cancers, Skin cancer
Results
Phase 1/2
This trial looked at HMBD-001 for that had spread into the surrounding tissue or to another part of the body. These are called advanced solid cancers or advanced solid tumours. The trial was supported by Cancer Research UK. People could join between 2021 and 2025. The team reported results in 2023 and 2026.
Recruitment start: 7 October 2021
Recruitment end: 31 July 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann De Bono
Cancer Research UK - regulatory@cancer.org.uk (trial sponsor)
Astellas Pharma Europe
The research team would like to thank all the patients who took part in this trial. By doing this, you’ve helped the research team learn more about cancer and how to treat it.
This is Cancer Research UK trial number CRUKD/22/002.
There is more information about this trial on ISRCTN, the UK’s clinical trial registry (ISRCTN62918594): A Phase I/IIa trial of HMBD-001 in advanced HER3-positive solid tumours
There is also more information about this trial on the clinicaltrials.gov website (NCT05919537): Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Last reviewed: 09 Sept 2026
CRUK internal database number: 17622
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
